➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:


Last Updated: April 11, 2021

DrugPatentWatch Database Preview

Litigation Details for Solas OLED Ltd. v. Samsung Display Co., Ltd. (E.D. Tex. 2019)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Solas OLED Ltd. v. Samsung Display Co., Ltd. (E.D. Tex. 2019)

Docket   Start Trial Date Filed 2019-05-02
Court District Court, E.D. Texas Date Terminated 2021-03-23
Cause 35:271 Patent Infringement Assigned To James Rodney Gilstrap
Jury Demand Both Referred To
Patents 10,029,015; 10,030,059; 10,046,031; 10,308,950; 10,383,950; 10,517,882; 6,612,945; 6,613,357; 6,978,945; 8,013,002; 8,613,950; 8,877,775; 8,945,612; 9,603,775
Attorneys Adam S Hoffman; Andrea Leigh Fair; Chang Sik Kim; Charles Everingham , IV; Claire Abernathy Henry; Daniel W. Cho; David A Garr; Grant D Johnson; Gregory Scott Dovel; Jared Frisch; Jeffrey Lerner; Jonas B Jacobson; Kent N. Shum; Marc A Fenster; Melissa Richards Smith; Neil Alan Rubin; Philip X Wang; Reza Mirzaie; Robert Thomas Haslam , III; Scott A Schrader; Sean Aaron Luner; Theresa M Troupson; Thomas John Ward , Jr
Firms Covington & Burling LLP - Washington DC; Dovel & Luner LLP; Gillam and Smith LLP; Russ August & Kabat - Los Angeles; Ward, Smith & Hill, PLLC
Link to Docket External link to docket
Small Molecule Drugs cited in Solas OLED Ltd. v. Samsung Display Co., Ltd.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in Solas OLED Ltd. v. Samsung Display Co., Ltd.

Details for Solas OLED Ltd. v. Samsung Display Co., Ltd. (E.D. Tex. 2019)

Date Filed Document No. Description Snippet Link To Document
2020-09-23 265 Transcript which we have to accomplish it, I'm going 10:29:15 20 to give each side 10 minutes to argue this…the patents-in-suit, 01:43:59 10 the '450 and '338 patents, and mapped the patents to OLED… 92 01:50:11 1 patent -- the '311 patent, the patent application was ever 01:50:13… light of this patent and the, quote, unquote, object of the 10:38:22 23 patent in order to prevent…elements are what the patent is talking about. And what 10:47:39 20 the patent says is that you External link to document
2020-04-17 99 Memorandum & Opinion layers as well. ’338 Patent at 10:42–47 (reproduced above). Nonetheless, “patent coverage is not …transistor array substrate (see ’338 Patent at 10:42–47 & 10:49–50): The common interconnection…emission type” embodiment in columns 10 and 11 of the ’338 Patent, “[Defendants’] proposed construction…transistor array substrate 50. ’338 Patent at 8:18–23, 10:42–51 & 11:50–52 (emphasis added). …surface of the planarization film 33” (’338 Patent at 10:48–49) is inconsistent with Defendants’ proposal External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.